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Summary.-Shortly after grafting of Ehrlich ascites carcinoma cells, the serum of
tumour-bearing mice loses the capacity to mediate immunoadherence phenomena,
because of a sharp decrease in the concentration of C3b and C3d, while the cellular
receptors for such factors are unaffected by tumour growth. Itis suggestedthatcom-
plement is consumed through the alternative pathway which is activated during the
inflammatory responses accompanying tumour growth.
THE failure ofcancer-bearing animals to
reject neoplastic cells may be attributed
not only to the impairment of their
immune reactivity, but also to a total or
partial lack of complement factors, which
are either congenital or caused by the
tumour itself. In fact complement deple-
tion impairs both the specific and non-
specific phenomena (i.e. phagocytosis and
B-lymphocyte stimulation (Mason, 1976))
and neutralizes the cytotoxicity of hum-
oral antibodies.
The serum concentration ofcomplement
fluctuates in many cases of human and
mouse leukaemia, showing a significant
decrease during the acute phases of the
disease and returning to a normal level
during remission (Yoshikawa, Yamada
and Yoshida, 1969). It has also been
reported that the serum of normal Swiss
mice, which is endowed with complement-
dependent cytotoxicity against leukaemic
cells of AKR mice, loses that property if
donor animals are grafted with Ehrlich
ascites tumour (Hartveit, 1964; Kassel et
al., 1973; Ting and Herberman, 1976).
Other researchers have been unable to
detect a marked decrease of the comple-
ment concentration in the sera of cancer-
ous hosts (Baltch et al., 1960; Bourdin et
al., 1964; Zarco, Flores and Rodriguez,
1964; Southam and Siegel, 1966; Verhae-
gen et al., 1976; Lichtenfeld, et at., 1976).
Most of these studies were performed by
titrating the serum haemolytic activity or
by single radial immunodiffusion, which
may not detect functional variations in
complement activity (Gewurtz and
Suyehira, 1976).
We felt that a better approach to the
understanding of complement behaviour
during cancer growth is offered by the
rosette method (Silveira, Mendes and
Tolnai, 1972), performed by using an
indicatorformedofsensitizederythrocytes,
complement and spleen cells from cancer-
bearing and normal mice.
MATERIALS AND METHODS
Mice.-Swiss albino mice, 12 weeks old,
were used.
Tumour.-Inocula of 107 cells of the half
diploid half tetraploid strain of the Ehrlich
ascites carcinoma (AT), were injected i.p. into
prospective donors of spleen cells.
Collection ofspleen cells.-3, 5, 7, 10 and 15
days after the i.p. injection of AT cells,
spleens were taken from tumour-bearing
animals, teased in cold Hanks' balanced salt
solution (HBSS) at pH 7-2, and the organ
fragments were flushed through a syringe.
Cell suspensions werefilteredthroughnylon
netting and washed x 3 with HBSS.
Preparation ofthe EACn, EACt and EACas
indicators.-1 ml ofa 5% suspension ofsheep
erythrocytes (E) was incubated with 1 ml of
a 1: 1000 dilution of anti-E rabbit serum atC. PORTA, M. L. VILLA AND E. CLERICI
37°C for 30 min. The sensitized cells (EA)
were washed x 3 with HBSS and a 5%
suspension was prepared in the same medium.
1 ml of the 5% EA suspension and 01 ml of
fresh serum from normal (Cn) or AT-bearing
mice (Ct) as source of complement was then
incubated at 37°C for 30 min. The cells
(EACn or EACt) were washed x3 in HBSS
and resuspended at a concentration of 1% in
HBSS. The EACt indicators were prepared
with serum of mice killed 3, 5, 7, 10 and 15
days after i.p. injection of AT cells (EACt3-
EACtl5); insome cases, theascitestakenfrom
mice 5, 7, 10 and 15 days after the i.p.
injection ofAT cells was used as the source of
complement (EACas5-EACasI5) (Cas3 was
not available because ascites fluid is not yet
formed 3 days after AT grafting). The source
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FIG. 1. Spleen cells (S) which have formed
rosettes with sheep erythrocytes (E), anti-
bodies to sheep erythrocytes (A), and com-
plement (C) from normal (n) and tumour-
bearing (t) mnice. Complement from Ehrlich
ascites is designated by C8S. The grey area
at the top of the figure represents the
range of normal values obtained by re-
acting Sn with EACn. Abscissa: Time of
collection of St, Ct and Ca. in days after
tumour grafting.
of anti-E antibody was a 2-mercaptoethanol-
sensitive rabbit antiserum to boiled E stroma,
which contained a high proportion of IgM to
IgG antibody (IgM: IgG=64) as previously
described (Clerici et al., 1976).
Test for rosette-forming cells.-To deter-
mine the percentage of rosette-forming
cells, 0 15 ml of 1% suspension of the EACn
or EACt indicator was mixed with an equal
amount of a suspension of normal (Sn) or
"cancerous" (St) spleen cells (5x 106/ml),
centrifuged at 200 g for 5 min and incubated,
without dispersing the pellet, at 370C for 30
min. The cell pellet was then gently dispersed
with a Pasteur pipette and the percentage of
rosette determined in a haemocytometer by
counting about 1000 cells. A lymphocyte was
scored as rosette-forming if 3 or more
erythrocytes adhered. Normal (Sn) and
cancerous spleen cells isolated at the time of
killing (St3-Stl5) were incubated with EACn
and EACt3-EACtI5 indicators, or with
EACas5-EACasI5.
C3b-inhibitor assay.-In a total volume of
1 ml, the EACn indicator was incubated with
a 10% final concentration of normal or
tumour-bearing serum collected 7 days after
AT grafting, heated at 560C for 30 min
(complement heat-inactivated=CnH56 or
CtH56). After 30 min at 370C, the cells were
washed x 3 in HBSS and resuspended to a
concentration of 1% in HBSS. The EACn/
CnH56 and EACn/CtH56 indicatorswere used
in the rosette test with Sn and St3-Stl5 cells,
as described above.
RESULTS
Rosetteformation with serum complement
As shown in Fig. 1, the number of
rosettes obtained by using the EACt3-
EACt15 indicators is inversely proportional
to the time elapsed from the i.p. injection
of AT cells and, one week after tumour
grafting, the number of rosettes is about
20% ofthat found in normal controls.
There were no significant differences
between St3-Stl5 and Sn cells, since the
slopes of the curves of the rosette-forming
cells obtained for each killing time by
incubating the EACt3-EACt,5 indicators
with Sn or St3-Stl5 cells were superimpos-
able. Furthermore, thenumbers ofrosettes
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FIG. 2. The columns show the number of
RFC/106 Sn or St with EACn preincubated
with 56'C-heated serum from normal
(CnH56) or tumour-bearing (CtH56) mice as
a source of C3b inactivator. CnH56 and
CtH56 are the abbreviated notations for
EAC./CnH56 andEACn/CtH56. Other sym-
bols as in Fig. 1.
formed by Sn or St3-Stl5 with the EACn
indicator were the same.
Rosette formation with ascites complement
The results obtained using the EACas5
EACasi5 indicators (also reported in Fig.
1) showthat: (1) Sn cellsformfewerrosettes
when incubated with EACas5-EACasl5
than with EACt3-EACt15 in the early per-
iod of tumour growth (3-5-7 days); and
(2) the number of EACas rosettes equals
that ofEACt rosettes 10-15 days after the
i.p. injection of AT cells.
Rosette formation after incubation of EACH
indicator with C3b-inactivating enzyme
As shown in Fig. 2, the number of
rosettes formed with EACn indicator
incubated with normal or tumour-bearing
heat-inactivated sera as source of C3b-
inactivating enzyme, is higher when Sn
rather than St3-StU5 cells are employed,
independently of the use of an EACII/
CnH56 or an EACn/CtH56 indicator. In
other words, the difference between sera
is not statistically significant, while
between cells it is (P<0 05).
DISCUSSION
Normal (Sn) and cancerous spleen cells
isolated at the time of killing (St3-StU5)
were incubated with EACn and EACt3-
EACt15 indicators in order to check at the
same time the capacity ofCt to react with
the EA complex, and the variations, if
any, ofthe number ofcellular receptors for
EACt and EACn.
Results, summarized in Fig. 1, show
that activity of cancerous serum as source
ofcomplement (Ct) is inversely proportion-
al to the time from the i.p. injection of
Ehrlich ascites carcinoma cells. One week
after tumour grafting, the number of
rosettes is about 20% of that found in
normal controls.
The decrease is not caused by modifica-
tion of the cellular membrane of the
lymphocytes of the AT-bearing mice,
since there are no significant differences
between St3-St5M and Sn cells. In fact the
slopes of the curves of the rosette-forming
cells obtained for each killing time by
incubating the EACt indicators with Sn
or St3-Stl5 cells were superimposable.
Furthermore, the numbers of rosettes
formed by Sn or St3-Stl5 with EACn in-
dicator were the same, thus showing that
the total amount of spleen cell receptors
for complement was not modified during
tumour growth. The experiments per-
formed by treating the EACn indicator
with the C3b-inactivating enzyme, which
splits C3b into C3d, which remains com-
plex-bound, and 2 minor peptides which
are released in the medium, showthat: (a)
serum from cancerous mice contains a
normal concentration of the enzyme; and
(b) Blymphocytes from the same animals
have a normal amount ofC3d receptors. It
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is known that macrophages have receptors
only for C3b, while B lymphocytes possess
also those for C3d, which arises through
the action of C3b-inactivating enzyme.
Our results (Fig. 2) show that the number
of Sn rosette-forming cells is higher than
that obtained with St3-St15 cells, inde-
pendently ofthe use ofan EACn/CnH56 or
an EACn/CtH56 indicator. In other words
the difference between sera is not statistic-
allysignificant, whilethatbetweencellshas
P<005. Such a difference may indicate
that B lymphocytes of cancer-bearing
mice have fewer C3d receptors than those
of normal mice. However, it is worth
remembering that the rosette assay has
beenperformed with spleen-cell suspension
containing both lymphocytes and macro-
phages. A relative increase of the number
of macrophages in the spleen of cancer-
bearing mice could explain the decreased
number ofrosettes formed afterincubation
of spleen cells with EACn complexes pre-
treated with C3b-inactivating enzyme
(CnH56 or CtH56) so that the stable C3d
site becomes accessible to cells which carry
C3dreceptors, like B lymphocytes. Indeed,
previous observations by ourselves showed
thatthe number ofmacrophages contained
in the spleen of mice grafted with AT cells
is significantly increased above controls
(Clerici et al., 1976). In view of these
findings, the smaller number of tumoral
spleen cells rosetting with EACn/CnH56
(or EACn/CtH56), that is, with EAC3d
complexes, can reasonably be correlated
with the relative increase in the number of
spleen macrophages brought about by the
growth ofthe transplanted tumour. There-
fore, it may be deduced that Swiss mice
bearing the AT cells lack the complement
factors responsible for immunoadherence,
while the cellular receptors for such factors
are unaffected by tumour growth.
It is difficult to define the mechanism of
this complement depletion and to deter-
mine whether it may affect the antitumor-
al reactivity of cancerous mice. If a hypo-
thesis can be formulated, it is possible that
complement is consumed through the
alternative pathway which is activated
during the inflammatory responses ac-
companying the tumour growth. The
alternative pathway represents the ances-
tral complement pathway, which can be
activated as a first line of defence through
several different and non-immune mechan-
isms. This hypothesis is supported by
measurement of the complement level in
the ascitic fluid (Cas) performed by using
the EACas5-EACas15 indicators in the
rosette method. The results (Fig. 1) show
that: (1) Sn cells form fewer rosettes when
incubated with ascites than with AT-
bearing serum in the early period of tum-
our growth (3-5-7 days); and (2) the
number of EACas rosettes equals that of
EACt rosettes 10-15 days after the i.p.
injection of Ehrlich ascites tumour cells.
It is possible that this behaviour is the
result of an excessive complement con-
sumption at the site of tumour implanta-
tion during the most active multiplication
of malignant cells, and the cancer-bearing
mice are unable to synthesize new comple-
ment in an amount sufficient to keep its
concentration constant in the body fluids,
as suggested by other authors (Kassel et
al., 1973; Irie, Irie and Morton, 1974;
Segerling, Ohanian and Borsos, 1976;
Bentley etal., 1976).
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